Seismic Therapeutic

Executive Summary

Seismic Therapeutic is a preclinical biotechnology company pioneering the integration of machine learning with immunology to develop optimized biologic medicines for autoimmune diseases. Founded in 2021 and based in Cambridge, Massachusetts, the company has raised $121 million to advance its proprietary IMPACT platform, which predicts protein properties and accelerates biologics discovery and engineering. By leveraging AI, Seismic aims to create safer, more effective therapies faster than traditional methods. The company is still in the preclinical stage, focusing on progressing its lead programs toward clinical development. With its innovative approach and strong funding, Seismic is positioned to address significant unmet needs in autoimmune indications, where biologic treatments often suffer from suboptimal efficacy and safety profiles. The team's expertise in computational biology and immunology provides a competitive edge in the rapidly evolving AI-driven drug discovery landscape.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Program60% success
• Q4 2026Series C Funding Announcement75% success
• Q2 2026Preclinical Data Presentation at Major Conference80% success